Novolog (Pharm-Up 1966) Ltd (NVLG.TA)

ILA 181.1

(0.39%)

EBITDA Summary of Novolog (Pharm-Up 1966) Ltd

Novolog (Pharm-Up 1966) Ltd's latest annual EBITDA in 2023 was 130.13 Million ILS , down -2.59% from previous year.
Novolog (Pharm-Up 1966) Ltd's latest quarterly EBITDA in 2024 Q2 was 37.84 Million ILS , down -40.65% from previous quarter.
Novolog (Pharm-Up 1966) Ltd reported an annual EBITDA of 138.52 Million ILS in 2022, up 19.75% from previous year.
Novolog (Pharm-Up 1966) Ltd reported an annual EBITDA of 115.92 Million ILS in 2021, up 15.52% from previous year.
Novolog (Pharm-Up 1966) Ltd reported a quarterly EBITDA of 37.84 Million ILS for 2024 Q2, down -40.65% from previous quarter.
Novolog (Pharm-Up 1966) Ltd reported a quarterly EBITDA of N/A for 2023 FY, down -2.59% from previous quarter.

Annual EBITDA Chart of Novolog (Pharm-Up 1966) Ltd (2023 - 2013)

Historical Annual EBITDA of Novolog (Pharm-Up 1966) Ltd (2023 - 2013)

Year	EBITDA	EBITDA Growth
2023	130.13 Million ILS	-2.59%
2022	138.52 Million ILS	19.75%
2021	115.92 Million ILS	15.52%
2020	104.05 Million ILS	43.83%
2019	70.26 Million ILS	31.91%
2018	52.62 Million ILS	17.29%
2017	44.84 Million ILS	-11.42%
2016	50.95 Million ILS	12.02%
2015	45.47 Million ILS	3.89%
2014	43.54 Million ILS	40.56%
2013	30.98 Million ILS	0.0%

Year	EBITDA	EBITDA Growth
2024 Q1	41.98 Million ILS	84.35%
2024 Q2	37.84 Million ILS	-40.65%
2023 FY	- ILS	-2.59%
2023 Q1	37.49 Million ILS	0.74%
2023 Q4	22.77 Million ILS	-31.51%
2023 Q2	36.79 Million ILS	-1.87%
2023 Q3	33.25 Million ILS	-9.63%
2022 Q1	33.87 Million ILS	25.47%
2022 FY	- ILS	19.75%
2022 Q4	37.22 Million ILS	12.31%
2022 Q3	33.14 Million ILS	-3.38%
2022 Q2	34.3 Million ILS	1.27%
2021 Q3	29.56 Million ILS	2.33%
2021 FY	- ILS	15.52%
2021 Q2	28.88 Million ILS	-6.53%
2021 Q1	30.9 Million ILS	32.2%
2021 Q4	26.99 Million ILS	-8.67%
2020 Q3	26.73 Million ILS	9.34%
2020 Q1	28.94 Million ILS	114.94%
2020 Q2	24.45 Million ILS	-15.53%
2020 FY	- ILS	43.83%
2020 Q4	23.37 Million ILS	-12.56%
2019 Q2	20.11 Million ILS	-7.45%
2019 FY	- ILS	31.91%
2019 Q4	13.46 Million ILS	0.22%
2019 Q3	13.43 Million ILS	-33.2%
2019 Q1	21.73 Million ILS	78.82%
2018 Q1	13.86 Million ILS	31.86%
2018 FY	- ILS	17.29%
2018 Q4	12.15 Million ILS	-6.8%
2018 Q3	13.04 Million ILS	-3.88%
2018 Q2	13.56 Million ILS	-2.12%
2017 Q2	11.11 Million ILS	-5.97%
2017 Q3	11.4 Million ILS	2.63%
2017 FY	- ILS	-11.42%
2017 Q4	10.51 Million ILS	-7.8%
2017 Q1	11.81 Million ILS	38.58%
2016 Q1	14.37 Million ILS	148.86%
2016 Q4	8.52 Million ILS	-33.88%
2016 FY	- ILS	12.02%
2016 Q3	12.89 Million ILS	-13.31%
2016 Q2	14.87 Million ILS	3.49%
2015 FY	- ILS	3.89%
2015 Q3	8.81 Million ILS	0.0%
2015 Q4	5.77 Million ILS	-34.45%
2014 FY	- ILS	40.56%
2013 FY	- ILS	0.0%

Peer EBITDA Comparison of Novolog (Pharm-Up 1966) Ltd

Name	EBITDA	EBITDA Difference